TCTMD’s Top 10 Most Popular News and Features for 2016
All year long, stories on bioresorbable scaffolds—both good news and bad—dominated our most-read lists, but so too did updates, approvals, and recalls from the valvular heart disease space. Cath lab hazards, approval of the Amplatzer PFO occluder, the EXCEL and NOBLE left main PCI trials, real-world data on non-vitamin K antagonist oral anticoagulants, and new cholesterol guidelines helped round out our top 10 list for the year 2016.
In the most talked about data from TCT 2016, investigators showed a two-fold higher risk of device-oriented clinical events with the “disappearing” scaffold as compared with Xience and no advantage in terms of vasomotor tone or late lumen loss.
An analysis of claims data, published in April, showed that both rivaroxaban and apixaban carry lower risks of intracranial hemorrhage versus warfarin when used in everyday practice for patients with nonvalvular A-fib.
The palpable air of sober second thoughts in several dedicated sessions at CRT 2016 appeared to stem from the sinking hopes that some of the hard-earned lessons in percutaneous aortic valve approaches would translate into swifter progress in the mitral space.
The two studies presented at TCT 2016 had enough data, with conflicting results, to make both cardiac surgeons and interventional cardiologists happy—and confused.
In August, Boston Scientific issued a voluntary recall for several lots of the Lotus Valve System due to breaks in the release mechanism of the delivery system. These breaks have resulted in three deaths from catastrophic vessel trauma, the company confirmed.
In the end, nine out of 10 panel members of the FDA’s Circulatory System Devices Panel felt the benefits of the Absorb BVS stent outweighed the risks, but the day-long meeting was not without some discord.
The mixed vote—nine versus seven on the question of efficacy—came after two decades of controversy, failed trials, and abandoned devices for a strategy that all but the most enthusiastic operators had stepped away from.
In data presented at the ACC 2016 Scientific Sessions, the latest iteration of the FDA-approved balloon-expandable transcatheter aortic valve proved itself superior to surgery among intermediate-risk patients in a matched-registry analysis.
According to one expert, many physicians might not want to think about the problems associated with radiation and other aspects of the job, but the hazards of the catheterization laboratory can no longer be ignored.
An update to recommendations in April, characterized as a “decision pathway,” specifically addresses the use of nonstatin therapies in patients unable to achieve sufficient LDL-cholesterol lowering.
Top 5 Feature Stories
We pride ourselves on taking a deep dive into stories tackling bigger themes or thornier questions. This is just a small selection of feature stories we served up in 2016. Find all our features stories here.
Top Blog Posts
Some of the most provocative opinions on TCTMD come from our Fellow Talk Blog, although I also spout off, occasionally, in the Editor’s Corner.